MLSS Quote, Financials, Valuation and Earnings

Biolase has a net margin of -58.13% compared to Milestone Scientific's net margin of -13.16%. Milestone Scientific's return on equity of -61.33% beat Biolase's return on equity of -21668.17%.

Milestone Scientific has a consensus price target of $2.13, signalling upside risk potential of 123.68%. On the other hand Biolase has an analysts' consensus of $1.2000 which suggests that it could grow by 16160.16%. Given that Biolase has higher upside potential than Milestone Scientific, analysts believe Biolase is more attractive than Milestone Scientific.

Milestone Scientific has a beta of 1.124, which suggesting that the stock is 12.429% more volatile than S&P 500. In comparison Biolase has a beta of 0.211, suggesting its less volatile than the S&P 500 by 78.874%.

Milestone Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biolase offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Milestone Scientific pays -- of its earnings as a dividend. Biolase pays out -- of its earnings as a dividend.

Milestone Scientific quarterly revenues are $2.5M, which are smaller than Biolase quarterly revenues of $10.9M. Milestone Scientific's net income of -$1.5M is lower than Biolase's net income of -$1.4M. Notably, Milestone Scientific's price-to-earnings ratio is -- while Biolase's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Milestone Scientific is 8.76x versus 0.01x for Biolase. Usually stocks with elevated PS ratios are considered overvalued.

Envista Holdings has a net margin of -58.13% compared to Milestone Scientific's net margin of 0.18%. Milestone Scientific's return on equity of -61.33% beat Envista Holdings's return on equity of -32.33%.

Milestone Scientific has a consensus price target of $2.13, signalling upside risk potential of 123.68%. On the other hand Envista Holdings has an analysts' consensus of $19.83 which suggests that it could grow by 22.43%. Given that Milestone Scientific has higher upside potential than Envista Holdings, analysts believe Milestone Scientific is more attractive than Envista Holdings.

Milestone Scientific has a beta of 1.124, which suggesting that the stock is 12.429% more volatile than S&P 500. In comparison Envista Holdings has a beta of 1.120, suggesting its more volatile than the S&P 500 by 12.044%.

Milestone Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Envista Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Milestone Scientific pays -- of its earnings as a dividend. Envista Holdings pays out -- of its earnings as a dividend.

Milestone Scientific quarterly revenues are $2.5M, which are smaller than Envista Holdings quarterly revenues of $652.9M. Milestone Scientific's net income of -$1.5M is lower than Envista Holdings's net income of $1.2M. Notably, Milestone Scientific's price-to-earnings ratio is -- while Envista Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Milestone Scientific is 8.76x versus 1.11x for Envista Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Solventum has a net margin of -58.13% compared to Milestone Scientific's net margin of 1.49%. Milestone Scientific's return on equity of -61.33% beat Solventum's return on equity of 9.76%.

Milestone Scientific has a consensus price target of $2.13, signalling upside risk potential of 123.68%. On the other hand Solventum has an analysts' consensus of $80.89 which suggests that it could grow by 22.1%. Given that Milestone Scientific has higher upside potential than Solventum, analysts believe Milestone Scientific is more attractive than Solventum.

Milestone Scientific has a beta of 1.124, which suggesting that the stock is 12.429% more volatile than S&P 500. In comparison Solventum has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Milestone Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Solventum offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Milestone Scientific pays -- of its earnings as a dividend. Solventum pays out -- of its earnings as a dividend.

Milestone Scientific quarterly revenues are $2.5M, which are smaller than Solventum quarterly revenues of $2.1B. Milestone Scientific's net income of -$1.5M is lower than Solventum's net income of $31M. Notably, Milestone Scientific's price-to-earnings ratio is -- while Solventum's PE ratio is 24.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Milestone Scientific is 8.76x versus 1.39x for Solventum. Usually stocks with elevated PS ratios are considered overvalued.

Dentsply Sirona has a net margin of -58.13% compared to Milestone Scientific's net margin of -47.51%. Milestone Scientific's return on equity of -61.33% beat Dentsply Sirona's return on equity of -32.39%.

Milestone Scientific has a consensus price target of $2.13, signalling upside risk potential of 123.68%. On the other hand Dentsply Sirona has an analysts' consensus of $18.43 which suggests that it could grow by 32.1%. Given that Milestone Scientific has higher upside potential than Dentsply Sirona, analysts believe Milestone Scientific is more attractive than Dentsply Sirona.

Milestone Scientific has a beta of 1.124, which suggesting that the stock is 12.429% more volatile than S&P 500. In comparison Dentsply Sirona has a beta of 0.918, suggesting its less volatile than the S&P 500 by 8.232%.

Milestone Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dentsply Sirona offers a yield of 4.59% to investors and pays a quarterly dividend of $0.16 per share. Milestone Scientific pays -- of its earnings as a dividend. Dentsply Sirona pays out -13.85% of its earnings as a dividend.

Milestone Scientific quarterly revenues are $2.5M, which are smaller than Dentsply Sirona quarterly revenues of $905M. Milestone Scientific's net income of -$1.5M is higher than Dentsply Sirona's net income of -$430M. Notably, Milestone Scientific's price-to-earnings ratio is -- while Dentsply Sirona's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Milestone Scientific is 8.76x versus 0.75x for Dentsply Sirona. Usually stocks with elevated PS ratios are considered overvalued.